

November 17, 2025

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai – 400 001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G - Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai – 400 051

Dear Sir(s),

**Sub: Intimation about Second Brand partnership between AstraZeneca Pharma India Limited ("Company") and Sun Pharmaceuticals Industries Limited for Sodium Zirconium Cyclosilicate powder for oral suspension 5 g**

Please find enclosed the copy of press release in connection with a Distribution Services Agreement entered into by the Company with Sun Pharmaceuticals Industries Limited for the distribution of Sodium Zirconium Cyclosilicate powder for oral suspension 5 g in India.

Further, please find the details as required under the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 attached herewith as **Annexure – A**, in this regard.

Kindly take the above information on record.

**For AstraZeneca Pharma India Limited**

Manasa. R

Company Secretary

**PRESS RELEASE****AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India**

**[BENGALURU/MUMBAI, INDIA] – [November 17, 2025]** – AstraZeneca Pharma India Limited ('AstraZeneca'), a leading science-led biopharmaceutical company (BSE : 506820, NSE : ASTRAZEN) and Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies), today announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India.

Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorization along with the import license of the molecule.

**Praveen Rao Akkinepally, Country President & Managing Director AstraZeneca Pharma India Limited said,** "At AstraZeneca, we aim to transform care with a focus on increasing early screening, diagnosis, and adoption of guideline-directed medical therapy to improve patient outcomes. This partnership with Sun Pharma for SZC reaffirms AstraZeneca's purpose to deliver innovative, life-changing medicines to patients with Hyperkalaemia across India, coupled with building robust pathways to reach patients in need. With this step, we are poised to significantly expand the reach of this vital therapy and help address the disease burden".

**Kirti Ganorkar, Managing Director, Sun Pharmaceutical Industries Limited said,** "We are delighted to join hands with AstraZeneca to address the growing challenge of Hyperkalaemia in India. The addition of SZC to our portfolio underscores our unwavering commitment to improving the care of patients with chronic kidney disease. As India's largest pharmaceutical company and a leader in this therapy area, we remain focused on expanding access to innovative treatments that empower healthcare professionals and enhance the quality of life for patients."

Hyperkalaemia is a clinically significant condition that disproportionately affects patients with chronic kidney disease (CKD) and those with heart failure (HF) receiving renin–angiotensin–aldosterone system (RAAS) inhibitor therapy, which can elevate serum potassium levels <sup>[1,2]</sup>. Prevalence estimates suggest that Hyperkalaemia occurs in up to 50% of patients with CKD and 42% of patients with chronic HF <sup>[3]</sup>. To manage or prevent recurrence, RAAS inhibitor therapy is often reduced or discontinued, which may compromise cardiorenal outcomes and increase mortality risk. <sup>[2,4]</sup> In India, mortality associated with Hyperkalaemia has been reported at 22.2% <sup>[5]</sup>. Sodium zirconium cyclosilicate (SZC) offers a rapid, effective, and generally well-tolerated treatment option for the management of Hyperkalaemia <sup>[6–9]</sup>.

Sun Pharma is the largest pharmaceutical company in India, with an 8.3% market share<sup>10</sup> and ranks No. 1 in prescriptions across 13 different doctor categories<sup>11</sup>. With a 15,000-strong field force, the company leads in chronic therapies and maintains a strong presence in the acute segment.

Building upon AstraZeneca's ambition to advance science, transform care and help manage life threatening conditions like Hyperkalaemia, this strategic step is a significant move in improving the management of Hyperkalaemia in India; promising enhanced availability to a crucial treatment and ultimately contributing to better patient outcomes nationwide.

## Notes:

### About AstraZeneca India

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 800 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization.

Marking its 45 years in India, AstraZeneca's innovative medicine portfolio covers therapy areas including Oncology; Biopharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology); and Rare Disease in the country and is focused on transforming the future of healthcare by unlocking the power of what science can do for people, society and planet. To know more, please visit [www.astrazeneca.com/india](http://www.astrazeneca.com/india) or follow us on [LinkedIn](#).

### About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and oncology and accounts for about 20% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) and follow us on LinkedIn & X (Formerly Twitter).

### References:

1. De Nicola L et al. Intern Emerg Med. 2024 Mar;19(2):295-306.
2. Kuijvenhoven MA et al. Int J Clin Pharm. 2013 Dec;35(6):1099-104.
3. Epstein M et al. Am J Manag Care. 2015 Sep;21(11 Suppl):S212-S220.
4. AlSahow A et al. J Clin Hypertens (Greenwich). 2023 Mar;25(3):251-258.
5. Bharathi Ramesh et al. *Journal of the Indian Academy of Geriatrics* 20(2):p 70-74, Apr-Jun 2024.
6. Kosiborod M et al. JAMA. 2014 Dec 3;312(21):2223-33.
7. Packham D et al. New Engl J Med. 2015; 372:222-31.
8. Ash S et al. Kidney Int. 2015; 88, 404-411.
9. Fishbane S et al. Poster presentation at: American Society of Nephrology Kidney Week 2017; November 2017; New Orleans, LA. Abstract #2759765
10. As per AIOCD AWACS data for 12 months ended June'25
11. As per SMSRC data for Mar-Jun'25

### Contacts: AstraZeneca India

#### Investors:

Manasa R  
Company Secretary  
Tel +91 80 6774 8000  
E-mail [manasa.r1@astrazeneca.com](mailto:manasa.r1@astrazeneca.com)

#### Media:

Gunjan Gupta  
Lead Corporate Communications & Sustainability  
Mobile +91 9663420314  
Email [gunjan.gupta1@astrazeneca.com](mailto:gunjan.gupta1@astrazeneca.com)

### Contacts: Sun Pharma

#### Investors:

Dr. Abhishek Sharma  
Tel +91 22 4324 4324, Ext 2929  
Tel Direct +91 22 43242929  
Mobile +91 98196 86016  
E-mail [abhi.sharma@sunpharma.com](mailto:abhi.sharma@sunpharma.com)

#### Media:

Gaurav Chugh  
Tel +91 22 4324 4324, Ext 5373  
Tel Direct +91 22 4324 5373  
Mobile +91 98104 71414  
E-mail [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)

### Annexure - A

Sl. No.	Particulars	Details
1.	Name of the entity with whom the agreement	Sun Pharmaceuticals Industries Limited
2.	Area of agreement	Distribution Services Agreement
3.	Domestic/International	Domestic
4.	Share exchange ratio / JV ratio	NA
5.	Scope of business operation of agreement	Distribution Services Agreement
6.	Details of consideration received in agreement	Payment of Rs. 26 crores, comprising an upfront fee and sales milestone payments, to be received from Sun Pharmaceutical Industries Limited under the Distribution Services Agreement.
7.	Significant terms and conditions of agreement	Exclusive deal where the Distributor will distribute Sodium Zirconium Cyclosilicate powder for oral suspension 5 g under the brand name Gimliand, in the territory of India, as per the terms of the contract
8.	Whether the arrangement is within related party transactions	No
9.	Whether the promoter/promoter group/ group companies have any interest in the entity being acquired	NA
10.	Size of the entity	The revenue from operations of Sun Pharmaceuticals Industries Limited on consolidated basis for FY 2024-25 stood at 52,041 crores.
11.	Rationale and benefit expected	Improve reach to innovative AstraZeneca medicines in India by leveraging Sun's strong presence and coverage in chronic therapies, while maintaining a strong presence in the acute segment.